Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd stock KRW 2,211, price KRW 1,975, upside +11.9%, quality 47 out of 100. Rating: undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 1,800 KRW – 21,947 KRW · fair‑value band 1,385 KRW – 3,271 KRW · the 1,975 KRW price screens below the 2,211 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Daishin Balance No.6 Special Purpose Acquisition Co. in your weekly email
Every Wednesday you see whether Daishin Balance No.6 Special Purpose Acquisition Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kookjeon Pharmaceutical Co., Ltd. operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services.
Show moreShow less
The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support.
It develops electronic materials, such as antistatic agents, monomers and polymers with low dielectric constant, and UV curing agents; low-resistance electrolyte, phosphine, silane, and boron compounds; semiconductor materials; and carbazole, boric acid, and fluorene intermediates.
In addition, the company owns patents for its manufacturing methods. It serves pharmaceuticals, intermediate products, new drug synthesis, and related materials industries. The company was founded in 1972 and is headquartered in Anyang-si, South Korea.
Stock analysis
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) currently trades at 1,975 KRW, while our model-based Fair Value estimate is 2,211 KRW, implying the stock looks roughly 11% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 2,530 KRW per share, and 5 of the 9 models we run sit above the 1,975 KRW price.
Bear case: the Multiples group reads lowest at 1,094 KRW, and 4 of the 9 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,385 KRW (bear) to 3,271 KRW (bull), the price of 1,975 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd reported revenue of 131B KRW in FY2025 versus 85.4B KRW in FY2021, a compound +11.3%/yr. Reported net income was −4.3B KRW in FY2025.
Key figures
Market cap 107B KRW (≈ $78.8M) Micro · P/S ratio 0.85 · EPS (TTM) −34.23 KRW · Dividend yield 0.4% · Net margin −1.4% · Return on equity −1.9% · Return on assets (EBIT) 1.6% (5-year average) · Operating margin 3.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 12%, 307750 screens cheaper than that median.
Fair Value models
Bear1,385 KRWFair Value 2,211 KRWBull3,271 KRW
Price 1,975 KRW · Upside +11.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.47/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.2% (2020) → −2.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.9% a year for the price.
Compare Daishin Balance No.6 Special Purpose Acquisition Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score47 · Bottom 25%
Fair Value upside+11.9% · Above median
Profitability
Return on assets−2.4% · Bottom 25%
Net margin (12 months)−1.4% · Bottom 25%
Operating margin (12 months)3.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)21.4% · Top 25%
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/307750
Frequently asked questions
Is Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,211 KRW versus a price of 1,975 KRW, about +12% upside (undervalued).
What is the fair value of 307750?
Our model-based fair value for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 2,211 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 1,975 KRW.
What is the quality score of 307750?
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Our model-based price target is the fair value of 2,211 KRW (as of Nov 9, 2026) from 10 valuation models. Cautious scenario 1,385 KRW, optimistic scenario 3,271 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daishin Balance No.6 Special Purpose Acquisition Co. Ltd stock forecast for 2026?
Our models put fair value at 2,211 KRW, about +12% upside versus a price of 1,975 KRW (undervalued). Cautious scenario 1,385 KRW, optimistic scenario 3,271 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd reported trailing-twelve-month revenue of about 135B KRW (latest available figure, as of Nov 9, 2026).
Does Daishin Balance No.6 Special Purpose Acquisition Co. Ltd pay a dividend?
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd currently shows a dividend yield of 0.43% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd has a dividend yield of 0.4%.
What growth is priced into Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
For today's price to be fair in a discounted-cash-flow model, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd would have to grow free cash flow by +6.1 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.2 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 307750 use?
Our models discount Daishin Balance No.6 Special Purpose Acquisition Co. Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.09, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daishin Balance No.6 Special Purpose Acquisition Co. Ltd that is +6.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) delivered so far?
Over the past 5 years revenue at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd grew +10.2 % a year. The price currently implies free-cash-flow growth of +6.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (+6.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The free-cash-flow yield on the price is 7.49 %: that much free cash flow Daishin Balance No.6 Special Purpose Acquisition Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daishin Balance No.6 Special Purpose Acquisition Co. Ltd it is 2,211 KRW per share (as of Nov 9, 2026), against a price of 1,975 KRW. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Daishin Balance No.6 Special Purpose Acquisition Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 307750 trades below its calculated fair value: price 1,975 KRW, fair value 2,211 KRW, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 307750?
No. The price is what the market pays today (1,975 KRW); the fair value is what the company's own numbers justify (2,211 KRW). For Daishin Balance No.6 Special Purpose Acquisition Co. Ltd the two are 236.00 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daishin Balance No.6 Special Purpose Acquisition Co. Ltd worth?
The market values Daishin Balance No.6 Special Purpose Acquisition Co. Ltd at about 107B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 1,975 KRW; our models calculate a fair value of 2,211 KRW per share.
What do the bullish and bearish scenarios say about 307750?
Our models span a range for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd: cautious scenario 1,385 KRW, base 2,211 KRW, optimistic 3,271 KRW per share (as of Nov 9, 2026, price 1,975 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Balance-sheet figures for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (as of Nov 9, 2026): return on equity −1.9%, debt of 0.16 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 307750 from its 52-week high?
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd trades at 1,975 KRW, about 64% below its 52-week high of 5,540 KRW and 10% above the low of 1,800 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,211 KRW is for.
Which stocks are comparable to Daishin Balance No.6 Special Purpose Acquisition Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daishin Balance No.6 Special Purpose Acquisition Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 1,975 KRW, calculated fair value 2,211 KRW (+12%), Quality Score 47/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 307750 calculated?
We run Daishin Balance No.6 Special Purpose Acquisition Co. Ltd through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 2,211 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daishin Balance No.6 Special Purpose Acquisition Co. Ltd currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The closing price on Nov 6, 2026 was 1,975 KRW. Our model-based fair value is 2,211 KRW, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daishin Balance No.6 Special Purpose Acquisition Co. Ltd right now?
A fairly wide model range (1,385 KRW to 3,271 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
How large is the market capitalisation of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The market capitalisation of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 107B KRW (≈ $78.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The price-to-sales ratio of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 0.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Earnings per share at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd are −34.23 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The dividend yield of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The net margin of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is −1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The return on equity (ROE) of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is −1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
On an EBIT basis the return on assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
The operating margin of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Revenue at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is growing +21.4% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750)?
Earnings per share at Daishin Balance No.6 Special Purpose Acquisition Co. Ltd are growing +850% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) carry?
The net debt of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd is 37.5B KRW (fiscal year 2025, ≈ 5.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daishin Balance No.6 Special Purpose Acquisition Co. Ltd in the live analysis
One click puts Daishin Balance No.6 Special Purpose Acquisition Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026